LMAT

$82.171.52%1.23

Lemaitre Vascular Inc (LMAT)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$80.94

Offen:

$81.80

24-Stunden-Volumen:

46,137

Relatives Volumen:

0.17

Marktkapitalisierung:

$1.88B

Einnahmen:

$256.28M

Nettoeinkommen (Verlust:

$62.40M

KGV:

30.28

EPS:

$2.71

Netto-Cashflow:

$79.12M

1W Leistung:

-2.54%

1M Leistung:

+4.07%

6M Leistung:

-26.66%

1Y Leistung:

-5.13%

1-Tages-Spanne:

$81.48$82.39

1-Wochen-Bereich:

$80.03$85.65

52-Wochen-Spanne:

$78.22$118.01

Lemaitre Vascular Inc Aktie (LMAT) Unternehmensprofil

Firmenname

Lemaitre Vascular Inc

Sektor

Healthcare

Branche

Medical Instruments & Supplies

Telefon

781-221-2266

Adresse

63 SECOND AVENUE, BURLINGTON, MA, USA

Mitarbeiter

655

@LMAT_Vascular

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

SEC

LMAT-Diskussionen auf X

LMAT vs. ISRG, BDX, ALC, RMD, MDLN vergleichen

Aktien	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LMAT Lemaitre Vascular Inc	$1.88B	$262.43M	$65.67M	$79.12M	$2.71
ISRG Intuitive Surgical Inc	$155.98B	$11.58B	$2.96B	$3.22B	$8.73
BDX Becton Dickinson Co	$54.33B	$20.84B	$941.00M	$3.07B	$3.94
ALC Alcon Inc	$35.68B	$224.23M	-$39.99M	$1.59B	$1.66
RMD Resmed Inc	$32.33B	$5.73B	$1.59B	$1.74B	$10.37
MDLN Medline Inc	$29.27B	$29.14B	$1.07B	$1.05B	$1.20

Lemaitre Vascular Inc Aktie (LMAT) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-08-05	Herabstufung	Barrington Research	Outperform → Mkt Perform
2025-08-06	Hochstufung	Barrington Research	Mkt Perform → Outperform
2025-02-28	Herabstufung	Barrington Research	Outperform → Mkt Perform
2025-02-28	Herabstufung	Oppenheimer	Outperform → Perform
2025-02-13	Eingeleitet	Wells Fargo	Equal Weight
2024-10-15	Eingeleitet	Cantor Fitzgerald	Neutral
2024-08-02	Resumed	Lake Street	Buy
2024-05-31	Resumed	ROTH MKM	Buy
2024-04-26	Hochstufung	Stifel	Hold → Buy
2024-02-06	Resumed	KeyBanc Capital Markets	Sector Weight
2023-10-23	Eingeleitet	JMP Securities	Mkt Outperform
2023-09-06	Eingeleitet	Oppenheimer	Outperform
2023-08-03	Herabstufung	Jefferies	Buy → Hold
2023-05-03	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-10-28	Herabstufung	Barrington Research	Outperform → Mkt Perform
2021-09-16	Eingeleitet	Jefferies	Buy
2021-02-12	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2020-03-16	Hochstufung	Sidoti	Neutral → Buy
2019-10-24	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-10-24	Hochstufung	Lake Street	Hold → Buy
2019-10-14	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2019-07-25	Bestätigt	Barrington Research	Outperform
2019-07-25	Hochstufung	First Analysis Sec	Neutral → Outperform
2018-10-08	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-10-08	Hochstufung	ROTH Capital	Neutral → Buy
2018-06-08	Resumed	ROTH Capital	Buy
2018-04-26	Herabstufung	Stifel	Buy → Hold
2018-04-26	Hochstufung	The Benchmark Company	Hold → Buy
2017-10-27	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2017-10-27	Herabstufung	The Benchmark Company	Buy → Hold
2017-07-10	Herabstufung	Canaccord Genuity	Buy → Hold
2017-07-10	Herabstufung	The Benchmark Company	Buy → Hold
2017-03-21	Eingeleitet	First Analysis Sec	Overweight
2017-02-22	Herabstufung	Barrington Research	Outperform → Mkt Perform
2016-09-22	Herabstufung	Sidoti	Buy → Neutral
2016-07-28	Bestätigt	Barrington Research	Outperform
2016-02-25	Bestätigt	Barrington Research	Outperform

Finanzdaten der Lemaitre Vascular Inc-Aktie (LMAT)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	249.60	219.86	193.48	161.65	154.42
Cost of revenue USD (M)	71.06	68.96	66.44	56.76	53.04
Gross profit USD (M)	178.54	150.90	127.05	104.90	101.38
Research and development USD (M)	14.14	15.65	16.97	13.29	11.80
Operating expenses USD (M)	110.63	98.65	90.34	78.07	64.96
Operating income USD (M)	67.91	52.26	36.71	26.83	36.43
Income before tax USD (M)	75.18	56.88	39.48	27.49	34.29
Income tax expense USD (M)	17.45	12.84	9.37	6.85	7.38
Net income USD (M)	57.73	44.04	30.11	20.64	26.91
Basic EPS USD/shares	2.55	1.96	1.36	0.94	1.27
Diluted EPS USD/shares	2.52	1.93	1.34	0.93	1.25
Basic weighted shares shares (M)	22.64	22.45	22.22	21.98	21.16
Diluted weighted shares shares (M)	22.93	22.78	22.42	22.17	21.48

Lemaitre Vascular Inc-Aktie (LMAT) Insiderhandel

BRIDGET A ROSSJul 29 '26
Director
Transaktion
Proposed Sale
Kosten
$103.94
#Aktien
4,322
Wert ($)
449,241
#Aktien Gesamt
0
TRENT G KAMKEMay 08 '26
Officer
Transaktion
Proposed Sale
Kosten
$107.00
#Aktien
2,928
Wert ($)
313,287
#Aktien Gesamt
0
Kamke Trent GMay 08 '26
Senior V. P., Operations
Transaktion
Sale
Kosten
$107.00
#Aktien
2,928
Wert ($)
313,287
#Aktien Gesamt
3,749
LeMaitre George WMay 08 '26
Chairman and CEO
Transaktion
Sale
Kosten
$108.69
#Aktien
27,881
Wert ($)
3,030,400
#Aktien Gesamt
1,430,019
Jasinski Lawrence JMay 07 '26
Director
Transaktion
Option Exercise
Kosten
$65.92
#Aktien
2,858
Wert ($)
188,412
#Aktien Gesamt
8,657
Jasinski Lawrence JMay 07 '26
Director
Transaktion
Sale
Kosten
$110.00
#Aktien
3,943
Wert ($)
433,730
#Aktien Gesamt
4,714
BRIDGET A ROSSMay 07 '26
Director
Transaktion
Proposed Sale
Kosten
$111.10
#Aktien
5,044
Wert ($)
560,366
#Aktien Gesamt
0
LAWRENCE J. JASINSKIMay 07 '26
Director
Transaktion
Proposed Sale
Kosten
$110.00
#Aktien
3,943
Wert ($)
433,730
#Aktien Gesamt
0
LeMaitre George WMay 07 '26
Chairman and CEO
Transaktion
Sale
Kosten
$107.64
#Aktien
18,600
Wert ($)
2,002,013
#Aktien Gesamt
1,457,900
Ross Bridget AMay 07 '26
Director
Transaktion
Option Exercise
Kosten
$48.15
#Aktien
5,044
Wert ($)
242,882
#Aktien Gesamt
8,986

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
BRIDGET A ROSS	Director	Jul 29 '26	Proposed Sale	$103.94	4,322	449,241	0
TRENT G KAMKE	Officer	May 08 '26	Proposed Sale	$107.00	2,928	313,287	0
Kamke Trent G	Senior V. P., Operations	May 08 '26	Sale	$107.00	2,928	313,287	3,749
LeMaitre George W	Chairman and CEO	May 08 '26	Sale	$108.69	27,881	3,030,400	1,430,019
Jasinski Lawrence J	Director	May 07 '26	Option Exercise	$65.92	2,858	188,412	8,657
Jasinski Lawrence J	Director	May 07 '26	Sale	$110.00	3,943	433,730	4,714
BRIDGET A ROSS	Director	May 07 '26	Proposed Sale	$111.10	5,044	560,366	0
LAWRENCE J. JASINSKI	Director	May 07 '26	Proposed Sale	$110.00	3,943	433,730	0
LeMaitre George W	Chairman and CEO	May 07 '26	Sale	$107.64	18,600	2,002,013	1,457,900
Ross Bridget A	Director	May 07 '26	Option Exercise	$48.15	5,044	242,882	8,986

Lemaitre Vascular Inc Aktie (LMAT) Neueste Nachrichten

Oct 31, 2026